Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Surg Pathol ; 29(8): 882-886, 2021 Dec.
Article in English | MEDLINE | ID: mdl-33827325

ABSTRACT

Acinic cell carcinoma of the breast is a rare subtype of triple-negative breast cancer that recapitulates the appearance of tumors seen in salivary glands. We present the case of a 42-year-old woman with an irregular, nontender mass above the left nipple during routine obstetric appointment at 24 weeks gestation. She was subsequently diagnosed with triple-negative invasive ductal carcinoma of the left breast, Nottingham grade 3, via core needle biopsy. She was treated with neoadjuvant therapy (doxorubucin and cyclophosphamide) antenatally and paclitaxel in the postpartum period followed by left mastectomy with sentinel node biopsy. The carcinoma in the mastectomy specimen showed a spectrum of morphologic patterns with immunohistochemistry revealing strong positivity for alpha-1-antichymotrypsin, epithelial membrane antigen (EMA), lysozyme, and S100. The histomorphology paired with the immunoprofile led us to the diagnosis of acinic cell carcinoma. We retrospectively performed immunostains in the core biopsy specimen, which demonstrated GATA-3 and DOG-1 positivity. Next-generation sequencing of the postneoadjuvant specimen using a 70-gene panel revealed 2 single-nucleotide variant (SNV) mutations: tumor protein 53 (TP53) (c.747G>T) SNV mutation and rearranged during transfection (RET) (c.2899G>A) SNV mutation.


Subject(s)
Biomarkers, Tumor/analysis , Breast/pathology , Carcinoma, Acinar Cell/diagnosis , Pregnancy Complications, Neoplastic/diagnosis , Triple Negative Breast Neoplasms/diagnosis , Adult , Anoctamin-1/analysis , Anoctamin-1/metabolism , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Breast/surgery , Carcinoma, Acinar Cell/genetics , Carcinoma, Acinar Cell/pathology , DNA Mutational Analysis , Female , GATA3 Transcription Factor/analysis , GATA3 Transcription Factor/metabolism , High-Throughput Nucleotide Sequencing , Humans , Immunohistochemistry , Mastectomy , Neoplasm Proteins/analysis , Neoplasm Proteins/metabolism , Polymorphism, Single Nucleotide , Pregnancy , Pregnancy Complications, Neoplastic/genetics , Pregnancy Complications, Neoplastic/pathology , Proto-Oncogene Proteins c-ret/genetics , Sentinel Lymph Node Biopsy , Triple Negative Breast Neoplasms/genetics , Triple Negative Breast Neoplasms/pathology , Tumor Suppressor Protein p53/genetics
3.
Int J Surg Pathol ; 27(2): 225-229, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30149737

ABSTRACT

NUT (nuclear protein in testis) carcinoma (NC) is an aggressive carcinoma characterized by rearrangements of the NUT gene on chromosome 15q14. Histologically, it is a poorly differentiated carcinoma composed of monotonous, medium-sized, round cells with scant amphophilic or eosinophilic cytoplasm. Foci of abrupt keratinization are often seen. In this report, we compare the morphology of 2 cases of NC. The first case shows characteristic features of uniform, round epithelioid cells admixed with foci of abrupt keratinization. The second case demonstrates nests of epithelioid-polygonal cells that appear to be loosely cribriform within a mucoid stroma. Although considered rare, the actual incidence of NC may be underestimated, as it is likely that many go undiagnosed because the morphology deviates from what is typical. Our report demonstrates that NC should always be considered in any case of an undifferentiated carcinoma and should not be excluded if typical histologic and immunohistochemical features of squamous differentiation are lacking.


Subject(s)
Carcinoma/pathology , Lung Neoplasms/pathology , Nuclear Proteins/metabolism , Oncogene Proteins/metabolism , Tracheal Neoplasms/pathology , Aged , Biomarkers, Tumor/analysis , Humans , Male , Neoplasm Proteins , Young Adult
5.
Transplantation ; 98(2): 148-56, 2014 Jul 27.
Article in English | MEDLINE | ID: mdl-24918615

ABSTRACT

BACKGROUND: Renal ischemia-reperfusion (I/R) is a major contributor to delayed graft function after renal transplantation. The pathophysiology of I/R can be summarized by a primary energy deficit during ischemia and a secondary phase of oxidative stress and inflammation. Sirtuin 1 is an energy-sensing enzyme involved in regulating multiple cellular functions. We hypothesized that stimulating Sirtuin 1 would increase mitochondrial biogenesis thereby enhancing energy metabolism and attenuating I/R-induced renal injury. METHODS: Adult male rats were subjected to 60 min of bilateral renal pedicle clamping. SRT1720 (5 mg/kg body weight) or vehicle (20% dimethyl sulfoxide in saline) was administered intravenously at reperfusion. Blood and renal tissues were collected 24 hr after reperfusion. RESULTS: Posttreatment with SRT1720 significantly improved renal histologic architecture, decreased apoptosis, and reduced serum aspartate aminotransferase and creatinine levels compared to the vehicle. Renal adenosine triphosphate (ATP) levels were reduced by 48% after I/R, whereas SRT1720 restored ATP to 77% of control. Further, SRT1720 reversed the loss of renal mitochondrial mass induced by I/R supported by an increased expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha and its downstream mediators. SRT1720 also increased ATP levels and mitochondrial mass in human renal HK-2 cells. Moreover, SRT1720 decreased the levels of malondialdehyde, nitrotyrosine, and inducible nitric oxide synthase expression compared to the vehicle. A marked decrease in macrophage infiltration by SRT1720 treatment was associated with a decrease in tumor necrosis factor-α expression and a decrease in IκB-α degradation and nuclear factor-κB phosphorylation after I/R. CONCLUSION: SRT1720 treatment enhanced energy metabolism by stimulating mitochondrial biogenesis as well as decreasing nitrosative stress and inflammation, thereby attenuating I/R-induced renal injury.


Subject(s)
Enzyme Activators/pharmacology , Heterocyclic Compounds, 4 or More Rings/pharmacology , Kidney Diseases/prevention & control , Kidney/drug effects , Mitochondrial Turnover/drug effects , Reperfusion Injury/prevention & control , Sirtuin 1/metabolism , Animals , Cell Line , Disease Models, Animal , Energy Metabolism/drug effects , Enzyme Activation , Humans , Inflammation Mediators/metabolism , Kidney/enzymology , Kidney/pathology , Kidney Diseases/enzymology , Kidney Diseases/pathology , Male , Oxidative Stress/drug effects , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolism , Reperfusion Injury/enzymology , Reperfusion Injury/pathology
6.
Article in English | MEDLINE | ID: mdl-23958552

ABSTRACT

AIM: To determine if PAX-8, CD5, and CD117 can differentiate thymic carcinoma from poorly differentiated lung carcinoma. DESIGN: Archived cases of thymic (n=13) and poorly differentiated lung (n=15) carcinoma were analyzed for intensity and proportion of expression of PAX-8, CD117, and CD5. RESULTS: PAX-8 was positive in 69.2% of thymic and 5.8% of lung carcinomas. CD117 was positive in 84% of thymic and 26.6% of lung carcinomas. A total of 53% of thymic and none of the lung carcinomas were positive for CD5. Forty-six percent, 53%, and 69% of thymic carcinomas were dual positive for combinations of CD5/PAX-8, CD117/CD5, and CD117/PAX-8, respectively. None of the lung carcinomas were dual positive. Positivity for any 2 of the 3 markers was seen in 84% of thymic and none of the lung carcinomas. Triple positivity was seen in 53% of thymic carcinomas. CONCLUSION: Adding PAX-8 to CD117 and CD5 increases the diagnostic yield for thymic carcinoma.


Subject(s)
Biomarkers, Tumor/metabolism , CD5 Antigens/metabolism , Carcinoma/diagnosis , Lung Neoplasms/diagnosis , Paired Box Transcription Factors/metabolism , Proto-Oncogene Proteins c-kit/metabolism , Thymus Neoplasms/diagnosis , Cell Differentiation , Cross Reactions , Diagnosis, Differential , Humans , Immunohistochemistry , PAX8 Transcription Factor
7.
N Am J Med Sci ; 5(4): 255-9, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23724399

ABSTRACT

Errors in potassium measurement can cause pseudohyperkalemia, where serum potassium is falsely elevated. Usually, these are recognized either by the laboratory or the clinician. However, the same factors that cause pseudohyperkalemia can mask hypokalemia by pushing measured values into the reference interval. These cases require a high-index of suspicion by the clinician as they cannot be easily identified in the laboratory. This article discusses the causes and mechanisms of spuriously elevated potassium, and current recommendations to minimize those factors. "Reverse" pseudohyperkalemia and the role of correction factors are also discussed. Relevant articles were identified by a literature search performed on PubMed using the terms "pseudohyperkalemia," "reverse pseudohyperkalemia," "factitious hyperkalemia," "spurious hyperkalemia," and "masked hypokalemia."

SELECTION OF CITATIONS
SEARCH DETAIL